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The human papillomavirus 
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High-risk human papillomaviruses (HPV) are the etiological pathogen of cervical and a number of 
ano-genital cancers. How HPVs overcome the significant barriers of the skin immune system has 
been the topic of intensive research. The E6 and E7 oncoproteins have emerged as key players in the 
deregulation of host innate immune pathways that are required for the recruitment of effector cells 
of the immune response. Here we demonstrate that E7, and to a lesser extend E6, strongly reduce 
NFκB activation in response to the inflammatory mediator imiquimod. Moreover, we establish that 
undifferentiated keratinocytes do not express the putative receptor for imiquimod, TLR7, and as such 
are stimulated by imiquimod through a novel pathway. Inhibition of imiquimod induced cytokine 
production required residues in the CR1 and CR3 regions of E7 and resulted in reduced nuclear 
translocation and acetylation of the p65 sub-unit of NFκB. The results provide further evidence 
for a TLR7-independent role of imiquimod in the epithelial immune response and reinforce the 
ability of the HPV oncoproteins to disrupt the innate immune response, which may have important 
consequences for establishment of a chronic infection.
Human papillomaviruses (HPVs) are small dsDNA viruses that infect the squamous epithelial cells of 
the skin epidermis, oropharyngeal and anogenital mucosa. Infection with HPVs is associated with a 
spectrum of clinical lesions, ranging from common warts to cancers. Greater than 100 types have been 
identified1 and they are classified as either low- or high-risk, depending on the association with cancer 
development. High-risk HPVs are responsible for the majority of cervical cancers and a growing sub-set 
of head and neck squamous cell carcinomas2, and amongst these HPV16 is detected in the majority of 
cases2. Carcinogenesis is linked to persistent infection with a high-risk virus that may last several years. 
This suggests that HPVs have evolved mechanisms to evade the immune system.
Several studies have focussed on the immune evasion capabilities of HPV and have demonstrated 
that three of the virus encoded proteins; E5, E6 and E7 can impact upon the host’s ability to mount an 
effective immune response. E5 is the lesser understood of the three oncoproteins3,4. It is a viroporin5 
that has been correlated with decreased cell surface expression of major histocompatibility complex 
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(MHC) molecules and reduced activation of the adaptive immune response6. E6 and E7 co-operate to 
down-regulate expression of the pro-inflammatory cytokines IL-18 and IL-87,8 and the chemo-attractants 
MCP-1 and MIP3α 9,10. In addition, they increase expression of the anti-inflammatory molecule IL-18 
binding protein (IL-18BP)11. As part of their immune evasion repertoire, both E6 and E7 have been 
shown to manipulate intracellular signalling pathways to inhibit activation of critical anti-viral transcrip-
tion factors including NFκ B and Interferon Regulatory Factors12–14.
Keratinocytes are the target for HPV infection. Studies have shown that keratinocytes can detect a 
wide range of pathogen associated molecular patterns (PAMPS) and respond by secreting a variety of 
cytokines and chemokines. These chemokines in turn recruit more specialised immune cells to the site 
of infection and initiate an immune response. The molecular basis for pathogen detection is an area of 
active investigation. Keratinocytes express a number of pattern recognition receptors (PRRs) including 
Toll-like receptors (TLRs). TLRs respond to a range of viral PAMPS including dsRNA (TLR3), hypo-
methylated DNA (TLR9) and ssRNA or imidazoquinoline compounds (TLR7/TLR8)15. The transcription 
factor NFκ B is activated by a number of inflammatory stimuli, including those sensed by TLRs, and 
plays a critical role in mediating anti-viral responses by regulating the expression of pro-inflammatory 
cytokines and interferons (IFNs). NFκ B is activated by phosphorylation and degradation of the inhib-
itory Iκ B protein, which frees NFκ B heterodimers to translocate from the cytoplasm to the nucleus, 
where they participate in the transcription of NFκ B target genes, including CCL20 and IL-616,17. NFκ B 
transcriptional activity is also controlled by post-translational modification of the NFκ B sub-units. These 
include acetylation of the p65 sub-unit, which regulates the DNA-binding abilities of NFκ B18,19.
Given the critical role of keratinocytes in eliciting the skin immune response to infection and the 
chronic nature of HPV infection, we sought to further understand the interplay between TLR signalling 
pathways and virus immune evasion strategies in primary human keratinocytes. We show that kerat-
inocytes mount an inflammatory response to a variety of virus-associated TLR ligands including the 
putative TLR7 ligand imiquimod. Somewhat surprisingly, we find that NFκ B activation in response to 
imiquimod is independent of TLR7 in keratinocytes. Moreover, we demonstrate that the major HPV 
oncoproteins E6 and E7 are able to block NFκ B activation in response to imiquimod treatment and that 
this is mediated by changes to nuclear translocation and p65 acetylation. Together these data provide 
further evidence for the TLR-independent activity of imiquimod and highlight the extensive immune 
evasion capacity of HPV.
Results
Expression of HPV E6/E7 inhibits NFκB activation in response to viral PAMPs in primary 
keratinocytes. The host immune response is critical for determining clearance or persistence of HPV 
infection. It has now become widely accepted that in addition to skin resident immune cells, infected 
keratinocytes can also act as sentinels and will respond to the presence of microbial PAMPs to acti-
vate the NFκ B transcription factor and drive a programme of cytokine and chemokine gene expres-
sion20. Despite this prominent role in initiating an immune response, their specific ability to respond to 
virus-associated PAMPs is not fully understood. To gain a clearer insight, we transfected primary human 
keratinocytes with a plasmid that drives luciferase expression from three copies of the NFκ B response 
element21 and treated cells with a panel of defined TLR ligands (Fig.  1). The TLR3 ligand poly-I:C, a 
synthetic analogue of double stranded viral RNA, lead to the strongest activation of NFκ B, as judged by 
levels of luciferase relative to untreated control (Fig. 1A). Keratinocytes also responded to treatment with 
the TLR9 ligand CpG-ODN and the imidazoquinoline imiquimod, a putative ligand for TLR7, although 
to a lower extent (Fig. 1A). To verify the results using a more physiologically relevant indicator, we ana-
lysed the media from mock and treated samples for levels of the chemokine CCL20 (Fig. 1B) and pro-in-
flammatory cytokine interleukin (IL)-6 (Fig. 1C). As NFκ B-dependent gene products, their expression 
was increased upon stimulation with all three TLR agonists and their relative levels mirrored the data 
obtained using the luciferase reporter system. Expression of the major HPV16 oncoproteins, E6 and E7, 
is correlated with reduced activation of immune signalling pathways in a number of experimental sys-
tems. To determine whether their expression impacted upon TLR-mediated NFκ B activation in a physi-
ologically relevant setting, primary human keratinocytes stably expressing a bicistronic E6/E7 transcript 
were assessed in parallel to control cells. Our findings support previously published data demonstrating 
that HPV oncoproteins dampen the inflammatory response mediated by TLR3 and TLR9 to varying 
levels22,23. They also provide the first evidence that E6/E7 expression suppresses signalling emanating 
from a putative TLR7 ligand in keratinocytes (Fig.  1A-C). It was important to ascertain whether the 
results obtained may have been as a result of overexpressing exogenous proteins. To control for this 
keratinocytes were generated expressing the NS3/4A protease of Bovine Viral Diarrhoea Virus (BVDV), 
a protein previously demonstrated not to modulate innate immune signalling pathways24. In agreement 
with our previous findings, expression of NS3/4A did not change levels of NFκ B-driven luciferase in 
response to the ligands tested (Fig. 1A). Taken together these data suggest that during a HPV infection, 
expression of the HPV oncoproteins would lead to an overall dampening of the innate immune response 
in the presence of virus PAMPS.
Imiquimod induces an inflammatory response in primary keratinocytes independent of TLR7 
expression. Studies demonstrate that imidazoquinoline molecules exert their inflammatory actions 
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through direct activation of signalling through TLR7 or TLR825,26 present on professional antigen pre-
senting cells including dendritic and Langerhans cells27. However, recent findings suggest that imiqui-
mod may have a more direct effect on epithelial cells28. This additional action has been suggested to 
occur independently of TLR7/TLR8 receptors28. To address this point we undertook a high-resolution 
analysis to uncover the transcriptional profiles of each of the TLR present in primary human keratino-
cytes (Table  1). The deep RNA sequencing technique (RNA-seq) permits the identification of multiple 
Figure 1. HPV16 oncoproteins disrupt TLR-mediated inflammatory signaling in primary human 
keratinocytes. (A) Primary human foreskin keratinocytes stably transduced with virus expressing pBabe-
Puro empty plasmid, pBabe-Puro-16E6/E7 oncoproteins or BVDV NS3/4A as a negative control were 
transfected with an NFκ B-dependent luciferase reporter plasmid40. A Renilla luciferase reporter plasmid 
(pRLTK) served as a transfection control. Transfected cells were subsequently treated with ligands to activate 
the anti-viral TLR proteins TLR3 (poly-I:C), TLR9 (CpG DNA) and TLR7 (Imiquimod) for 16 hours, before 
cells were lysed in Passive Lysis Buffer (Promega) and analysed using a dual luciferase system (Promega)24. 
Data are from five independent biological repeats and presented as fold increase in luciferase above the 
unstimulated pBabe-Puro. (B) CCL20 and (C) IL-6 protein levels in TLR-ligand stimulated cells. Cells were 
stimulated as in (A), and media was collected at 24 hours post-stimulation for analysis by ELISA for each 
cytokine. Data are presented as picograms of cytokine. Error bars are + /− SD and **indicates a p < 0.01, 
*p < 0.05, NS indicates not significant.
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transcripts in a single sample in an unbiased manner and can also be adapted to give quantitative data 
on transcript abundance. Accordingly, total polyadenylated cellular RNA was isolated from undifferen-
tiated human foreskin keratinocytes, reverse transcribed and total cDNAs were subjected to Illumina 
deep sequencing. The resulting short reads were processed and aligned to the human genome using the 
Integrated Genome Viewer. Quantitative data on the abundance of individual transcripts was obtained 
by normalising the number of reads to the length of the gene i.e. using reads per kilobase (of the gene) 
per million mapped reads (RPKM), a value indicative of the transcript’s abundance. Using this approach, 
transcripts were detected that aligned with TLR1, TLR2, TLR3, TLR5, TLR6, TLR9 and TLR10 although 
they were of relatively low abundance compared to the highly-expressed β 2-microglobulin transcript. 
We did not detect any reads (and therefore transcripts) corresponding to TLR4, TLR7 or TLR8. Thus 
our results demonstrating the effects of imiquimod treatment on NFκ B activation and secretion of 
the cytokines IL-6 and CCL20 in primary keratinocytes indicated an activity beyond TLR7 or TLR8. 
To validate these findings, keratinocytes were treated with imiquimod or an additional TLR7 ligand 
called CL264. CL264 is a 9-benzyl-8 hydroxyadenine derivative shown to trigger NFκ B activation at 
significantly lower concentrations than imiquimod. In these assays imiquimod but not CL264 was able 
to induce NFκ B-driven luciferase expression (Fig.  2A) and this was complimented with increases in 
CCL20 secretion from treated cells (Fig. 2B). To verify that CL264 was functional, HEK293 cells stably 
expressing TLR7 were incubated with imiquimod and CL264. In contrast to primary keratinocytes both 
ligands induced secretion of CCL20 and IL-6 into the cell media (Fig.  2C). Finally, to underscore the 
TLR-independent nature of the actions of imiquimod in this system, keratinocytes were pre-treated 
with a 26 amino acid peptide that blocks dimerization of the critical TLR adaptor protein Myeloid 
Differentiation primary response gene 88 (MyD88)29. As TLR7 signals through MyD88, addition of this 
peptide would be expected to block any TLR-mediating signalling event in response to imiquimod treat-
ment. As can be seen, addition of the MyD88 blocking peptide had no significant effect on imiquimod 
induced CCL20 secretion but was able to effectively prevent CCL20 secretion in response to CpG-DNA, 
a TLR9 ligand, which signals through MyD88 (Fig. 2D). Taken together these data indicate that primary 
human keratinocytes mount an inflammatory response to imiquimod that is independent of the canon-
ical imiquimod receptor, TLR7.
HPV E7 negatively regulates the imiquimod-induced inflammatory response in primary 
keratinocytes. To determine which of the two major HPV oncoproteins was able to prevent an 
inflammatory response to imiquimod treatment, keratinocytes were infected with retroviruses express-
ing HPV16 E6 and E7 in isolation or E6/E7 as a bicistronic transcript. Keratinocytes harbouring plasmid 
vector alone (mock) displayed an induction of NFκ B-driven luciferase in response to treatment with 
imiquimod (Fig.  3A), which was decreased in the presence of 16E6. Expression of 16E7 had the most 
pronounced impact on imiquimod-mediated NFκ B activation compared with control, which was not 
significantly further decreased by the co-expression of 16E6. These results were reflected in the levels of 
CCL20 and IL-6 secreted into the media of treated cells (Fig. 3B,C). These data suggest that whilst both 
oncoproteins can target the pro-inflammatory pathway, E7 is the major inhibitor of imiquimod-induced 
inflammatory responses in primary keratinocytes.
Transcript RPKM
Beta-2-microglobulin 26.54
TLR1 0.05
TLR2 0.16
TLR3 0.09
TLR4 0
TLR5 0.05
TLR6 0.56
TLR7 0
TLR8 0
TLR9 0.05
TLR10 0.01
Table 1. TLR expression profile in primary keratinocytes. Levels of TLR mRNAs in primary human 
keratinocytes were quantified from RNA-Seq data using the Cufflinks program with output expressed 
as reads per kilobase per million mapped reads (RKPM). This program generates normalised data that 
is proportional to the level of the transcript in the original population of cellular mRNAs. The levels of 
β 2-microglobulin (B2M) transcripts were included as a positive control.
www.nature.com/scientificreports/
5Scientific RepoRts | 5:12922 | DOi: 10.1038/srep12922
E7 proteins from other HPV types inhibit NFκB activation in response to imiquimod. To 
establish whether the inhibition of NFκ B activation was a general feature of E7 proteins, keratinocytes 
stably expressing E7 proteins from several mucosal types were treated with imiquimod and the levels 
of secreted IL-6 measured by ELISA (Fig. 3D). E7 from both low-risk (HPV6b, HPV11) and high-risk 
(HPV16, HPV18, HPV31) types prevented IL-6 production to comparable levels. These experiments 
illustrate that NFκ B is a conserved target for E7 proteins of multiple HPV types, suggesting that inhi-
bition of this inflammatory transcription factor may be necessary during the HPV life cycle rather than 
associated directly with transformation.
Mapping the regions of E7 necessary to inhibit NFκB activation in response to imiqui-
mod. Primary keratinocytes were transduced with retroviruses expressing E7 proteins containing 
mutations or small internal deletions in the amino terminal disordered conserved regions CR1 and 
CR2 or in the carboxyl-terminal region CR311,30. Figure 4A shows a schematic of the proteins examined 
in this study. E7 proteins containing a point mutation in the LxCxE motif (C24G) or three of the four 
short internal deletions in CR3 (∆1 (amino acids 52–56), ∆2 (amino acids 65–67) and ∆4 (amino acids 
79–83)) inhibited NFκ B activation to wild type levels (Fig. 4B). In contrast E7 proteins with a mutation 
in the second amino acid (H2P) or the ∆3 (amino acids amino acids 75-77) deletion in CR3 showed a 
Figure 2. Imiquimod mediated NFκB activation and inflammatory cytokine production is independent 
of TLR7 in keratinocytes. (A) Primary human foreskin keratinocytes were transfected with an 
NFκ B-dependent luciferase reporter plasmid. A Renilla luciferase reporter plasmid (pRLTK) served as a 
transfection control. Transfected cells were subsequently treated with the TLR7 ligands Imiquimod and 
CL264 for 16 hours, before cells were lysed in Passive Lysis Buffer (Promega) and analysed using a dual 
luciferase system (Promega). Data are from three independent biological repeats and presented as fold 
increase in luciferase above the unstimulated control. (B) Cells were stimulated as in (A), and media was 
collected at 24 hours post-stimulation for analysis by ELISA for CCL20 production. (C) Imiquimod and 
CL264 activate NFκ B-dependent transcription in a HEK293-TLR7 cell line. HEK293-TLR7 cells were 
transfected, stimulated and analysed as in (B) for CCL20 and IL-6. (D) Imiquimod-mediated cytokine 
production is MyD88-independent in keratinocytes. Keratinocytes were treated with a MyD88 inhibitory 
peptide or a control peptide prior to stimulation with Imiquimod or CpG ODN. Media was collected after 
24 hours and analysed for secreted CCL20 by ELISA. Data are presented as picograms of cytokine. Error 
bars are + /− SD. **p < 0.01 and NS indicates not significant.
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reduced ability to inhibit NFκ B transactivation (Fig.  4B). This failure to prevent NFκ B activation was 
further evidenced by the near wild type levels of CCL20 and IL-6 secreted from cells harbouring these 
mutants in response to imiquimod stimulation (Fig. 4C,D). It is plausible that the alteration or deletion 
of amino acids in E7 had impacted upon their overall folding or stability. Western blot confirmed stable 
expression of all proteins in keratinocytes, albeit at variable levels (Fig. 4A). Furthermore, previous work 
had demonstrated that all of the CR3 mutants retained the ability to induce pRb degradation11, suggest-
ing no gross changes in E7 structure. These data suggest that the beginning of CR1 (H2P) and a short 
region in CR3 are required for the inhibition of NFκ B in response to imiquimod.
E7 negatively regulates imiquimod-induced activation of NFκB by reducing its nuclear trans-
location and acetylation. We sought to determine how E7 inhibits NFκ B-dependent activation in 
response to imiquimod treatment. We addressed whether E7 negatively regulates imiquimod-induced 
NFκ B activation by acting upstream or downstream of the critical IKK complex, which plays a key role in 
the activation of NFκ B in response to a number of stimuli. To this end, keratinocytes stably harbouring 
empty plasmid or 16E7 were transfected with a constitutive active form of IKKβ in conjunction with the 
NFκ B-driven luciferase reporter construct. As shown in Fig. 5A, IKKβ increased NFκ B-driven luciferase 
levels above an empty plasmid control. Cells expressing E7 retained significantly decreased levels of lucif-
erase activity, despite equal expression of the DA-IKKβ as determined by western blot. This result sug-
gests that E7 negatively regulates imiquimod-induced NFκ B activation by acting downstream of IKKβ . 
Figure 3. HPV E7 proteins are potent inhibitors of NFκB-dependent transcription and cytokine 
production in keratinocytes. (A) Primary human foreskin keratinocytes stably transduced with virus 
expressing pBabe-Puro empty plasmid or pBabe-Puro-16E6/E7 oncoproteins were transfected with an 
NFκ B-dependent luciferase reporter plasmid. A Renilla luciferase reporter plasmid (pRLTK) served as a 
transfection control. Transfected cells were subsequently treated with Imiquimod for 16 hours, before cells 
were lysed in Passive Lysis Buffer (Promega) and analysed using a dual luciferase system (Promega). Data 
are from five independent biological repeats and presented as fold change compared to unstimulated pBabe-
Puro. (B) CCL20 and (C) IL-6 protein levels in Imiquimod stimulated cells. Cells were stimulated as in (A), 
and media was collected at 24 hours post-stimulation for analysis by ELISA for each cytokine. (D) E7 from 
multiple HPV types inhibits Imiquimod-induced cytokine expression. Primary human foreskin keratinocytes 
stably expressing E7 from multiple HPV types were stimulated with Imiquimod for 24 hours and levels 
of secreted IL-6 analysed by ELISA. Data are presented as picograms of cytokine. Error bars are + /− SD. 
**p < 0.01, *p < 0.05.
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To test whether impaired NFκ B transactivation was caused as a result of reduced nuclear import we 
stimulated control, wild-type E7 and E7∆3 expressing keratinocytes with imiquimod and enriched for 
the nuclear fraction. Samples were probed with antibodies directed against GAPDH (cytoplasmic) and 
Lamin B (nuclear) to verify the efficacy of the fractionation (Fig.  5B). Low levels of endogenous p65 
were detected in the nuclear fractions of untreated cells (Fig. 5B). By comparison, imiquimod treatment 
caused an increase in p65 levels in the nuclear fraction of control cells. In agreement with a previous 
report31, expression of wild-type E7 reduced p65 nuclear import. The E7∆3 mutant caused a similar 
reduction in p65 nuclear import implying that the CR3 region of E7 is not necessary for this function.
In addition to nuclear shuttling, post-translational modifications, particularly protein acetylation, play 
a critical role in regulating NFκ B activity by enhancing the DNA-binding ability of p65 for the κ B site32,19. 
Since E7 has previously been shown to interact with the pCAF acetyltransferase7,33, we hypothesised that 
Figure 4. Residues in CR1 and CR3 regions of E7 are necessary for inhibition of NFκB in response 
to imiquimod treatment. (A) Schematic of E7 and the mutations used in this study. Functional regions 
of E7 are highlighted. Substitutions are shown, and small deletions are indicated by “Δ ”. Cell lysates from 
representative experiments were subjected to SDS-PAGE and probed with the indicated antibodies to 
confirm E7 expression. GAPDH was used to demonstrate equal loading of lysates. (B) Primary human 
foreskin keratinocytes stably expressing empty plasmid (pBabe), 16E7, 16E7 H2P, 16E7 C24G, and four 
carboxyl-terminal truncations designated Δ 1 (with deletion of amino acids 52 to 56), Δ 2 (with deletion of 
amino acids 65 to 67), Δ 3 (with deletion of amino acids 75 to 77), and Δ 4 (with deletion of amino acids 
79 to 83) were treated with imiquimod for 16 h and assayed as described in Fig. 3. (C) CCL20 and (D) IL-6 
protein levels in Imiquimod stimulated cells in mock, E7 wild type, E7 H2P and E7Δ 3 expressing cells. 
Cells were stimulated as in (B), and media was collected at 24 hours post-stimulation for analysis by ELISA 
for each cytokine. Data are presented as picograms of cytokine. Error bars are + /− SD. **p < 0.01 and NS 
indicates not significant.
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an additional mechanism by which E7 may inhibit NFκ B activity, may involve preventing the acetylation 
of p65. To test this, control and E7 expressing keratinocytes were subjected to imiquimod treatment and 
levels of p65 acetylation determined by western blot with an acetylation specific antibody.  Imiquimod 
induced acetylation at lysine 310 (K310) was markedly reduced in E7 expressing cells compared to con-
trol (Fig. 5C). In cells expressing E7∆3 levels of p65 acetylation were similar to the control, suggesting 
that E7 was no longer able to prevent this critical post-translational modification event.
Figure 5. Nuclear translocation and p65 acetylation are reduced in E7 expressing cells.  
(A) Keratinocytes expressing empty plasmid (pBabe) or E7 wildtype were transfected with an 
NFκ B-dependent luciferase reporter plasmid, Renilla luciferase transfection control together with DA HA-
tagged IKKβ , and NFκ B-driven transcription analysed as in Fig. 2. Error bars are + /− SD. And **indicates 
p < 0.01. Expression of HA-IKKβ was confirmed by western blot. *denotes a non-specific band detected 
by the HA antibody. (B) Keratinocyte lines were mock or imiquimod treated and the nuclear fractions 
extracted with probed with antibodies against p65. The integrity of the nuclear fraction was determined by 
probing for markers of the cytoplasm (GAPDH) and nucleus (Lamin B). Representative gels are shown from 
3 biological repeats. (C) Total keratinocyte lysates from mock and imiquimod treated cells were probed with 
antibodies that detect total p65 and p65 acetylated at K311. Representative gels are shown from a total of 5 
biological repeats. All electrophoresis gels were run under the same experimental conditions.
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Discussion
Keratinocytes play a critical role as sentinels of the immune system. They can function as instigators 
of epithelial inflammation and are able to sense the presence of invading microorganisms, including 
viruses, as they encode a repertoire of PRRs. Keratinocytes are also important producers of antimicro-
bial molecules. Detection of virus encoded PAMPS culminates in the secretion of a milieu of cytokines 
that serve to activate and recruit key effector cells of the skin immune response. Despite this clear role 
for keratinocytes as instigators of the skin immune response, there are still many unresolved questions 
concerning the molecular basis for pathogen detection, intracellular signalling events in the infected 
keratinocyte and cellular interactions in the epidermis. Epitheliotropic viruses that establish chronic 
infections have evolved complex mechanisms to evade and subvert the skin immune response. In this 
regard, there is considerable literature to suggest that HPV utilises several strategies to dampen the host 
immune response.
We sought to address some of these outstanding issues by treating primary keratinocytes with a panel 
of ligands known to stimulate anti-viral PRRs and to determine whether HPV encoded oncoproteins 
were able to inhibit the inflammatory response. We show that E6 and E7 inhibited the activity of the tran-
scription factor NFκ B in response to a range of anti-viral PRR ligands including the putative TLR7 ligand 
imiquimod. As a consequence, keratinocytes secreted reduced amounts of NFκ B-dependent cytokines 
including IL-6 and the chemo-attractant CCL20. Reduced CCL20 secretion would have a detrimental 
effect on the ability of keratinocytes to recruit circulating antigen presenting cells to the site of infection. 
Of note, HPV infected skin lesions demonstrate significant reductions both in CCL20 expression and 
the number of infiltrating Langerhans cells compared to uninfected controls9,34. Reduced migration of 
effector cells to the site of virus infection would enable HPV to evade local detection by the immune 
system and contribute towards its ability to persist in the infected host.
Whilst there is previous evidence for inhibition of TLR3 and TLR9 signalling by HPV oncoproteins, 
less is understood regarding potential evasion of TLR7 mediated immunity in keratinocytes. We demon-
strated that both E6 and E7 were able to suppress NFκ B activation in response to imiquimod, although 
levels were reduced more in the presence of E7. There is controversy surrounding the role of TLR7 in 
activating the skin immune response to compounds including imiquimod. It has been proposed that 
the anti-viral properties of imiquimod are mediated by activation of TLR7 or TLR8 in skin infiltrating 
mononuclear cells27. However, isolated keratinocytes mount a robust inflammatory response to imiqui-
mod treatment. In addition, it has been reported that undifferentiated keratinocytes do not express TLR7 
or TLR8 and that imiquimod instead exert its effects on this population of cells through an alternative 
pathway, which may require adenosine receptors28. To investigate this, we used RNA-seq to study the 
transcriptome of primary keratinocytes. This allowed us to study cellular gene expression in great depth 
and with high specificity. The results of the sequencing analysis confirmed that undifferentiated primary 
keratinocytes do not express TLR4, TLR7 or TLR8. We verified these data using alternative TLR7 ligands, 
which were unable to induce cytokine production in primary keratinocytes but were capable of stimulat-
ing HEK293 cells stably expressing TLR7. Moreover, a small peptide inhibitor of MyD88 signalling also 
failed to prevent to imiquimod induced cytokine secretion in keratinocytes but was able to effectively 
block TLR9 mediated signalling. Similar findings have also been shown with imiquimod treated spleno-
cytes from MyD88-deficient mice28.
This unidentified pathway induced NFκ B activation in response to imiquimod treatment as evidenced 
by reporter assays and resulted in the production of NFκ B-dependent cytokine production (IL-6 and 
CCL20). Interestingly, this pathway was also effectively inhibited by E7 expression. A panel of estab-
lished E7 mutants was used to map the functional requirements for NFκ B inhibition11,35. We found 
that E7 proteins containing a point mutation in the CR1 region (H2P) or a small internal deletion in 
CR3 (amino acids 75–77) were unable to repress NFκ B activation to the same level as wildtype E7 and 
secreted cytokine levels similar to the control samples. One mechanism by which E7 perturbs imiquimod 
signalling might be by preventing the nuclear entry of NFκ B sub-units31. We confirmed that E7 partially 
suppresses p65 nuclear translocation and that the CR3 mutant that is unable to inhibit NFκ B activation 
to control levels was still able to impair nuclear translocation. These data suggested that E7 might pre-
vent NFκ B activation by additional mechanisms. For example H2 and CR3 regions might be required 
to interact with cellular proteins that are essential components of the NFκ B signalling pathway. In this 
regard, previous studies have linked an interaction between E7 and the histone deacetylase P/CAF with 
suppression of host cell transcription7. NFκ B-dependent transcription requires multiple co-activator pro-
teins, including histone acetyltransferases such as P/CAF18. In particular acetylation of lysine residues 
including K310 on the p65 sub-unit are essential for effective DNA binding by NFκ B18. Using acetylation 
specific antibodies we demonstrated that p65 acetylation was reduced in imiquimod treated cells express-
ing E7. These data suggest that E7 may interfere with histone acetyltransferase activity to suppress NFκ B 
activation. In support of this, mutation of the second amino acid of E7 (H2P) reduced the binding of E7 
to P/CAF7. In our assays this mutant was unable to suppress NFκ B activation and cytokine secretion in 
response to imiquimod. Whilst it is currently not known if the E7∆3 can bind P/CAF, it should be noted 
that a second study identified a point mutation in the CR3 region of E7 that ablated binding to P/CAF 
in a yeast-2-hybrid assay33. Together, these data suggest that multiple regions of E7 may be required for 
the interaction with P/CAF.
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From several studies and our data it can be concluded that keratinocytes respond to imiquimod 
through at least two pathways. One that requires TLR7 and may be active in differentiated keratino-
cytes36, and a second, poorly characterised, pathway in undifferentiated cells that lack TLR7 expression. 
By targeting NFκ B signalling, E7 effectively suppresses the anti-viral response to activation of either 
pathway. Our study now adds a further example of E7 immune evasion and suggests that expression of 
HPV oncoproteins provides a broad spectrum dampening of the cytokine response from infected kerat-
inocytes that would suppress the recruitment of effector cells to the site of infection and help explain 
HPV persistence in the epidermis. Furthermore, our findings are of importance for clinical treatment of 
epithelial infections and lesions since the inflammatory response of topical imiquimod application seems 
to be closely linked to the therapeutic effect. It has not yet been deciphered to what extent the efficacy of 
imiquimod relies on the epidermal response. Therefore, to further optimise treatment effect to side effect 
ratio and efficacy a better understanding of the response pathways to imiquimod will impact further 
pharmacotherapy developments.
Materials and Methods
Cell lines and viruses. Primary human foreskin keratinocytes were cultured as described37. Cells were 
grown in SFM keratinocyte growth media (Invitrogen) containing 25 mg/mL bovine pituitary extract and 
0.1 ng/mL EGF. Cells were passaged for a maximum of 6 passages. Stocks of retrovirus for transduction 
of keratinocytes were produced by transfection of the Phoenix packing cell line. Supernatants from trans-
fected cells were added to target cells with 5 μ g/mL polybrene at 37 °C. Virus was removed from cells 
after 6 hours incubation and cells were fed fresh media. After 48 hours recovery at 37 °C cells were placed 
under selection in 5 μ g/mL puromycin.
Plasmids. The plasmid pBabe-Puro was used to transiently or stably express E6 or E6/E7 prod-
ucts. Constructs containing E6, E7 or E6/E7 from HPV6, 11, 16 and 31 were provided by Prof. Dennis 
McCance (Queens, University Belfast) and were previously described7. HPV18 E7 sequences were PCR 
amplified from full-length HPV18 genome37 and ligated into pBabe-Puro using BamHI and EcoRI sites. 
HPV16 E7 point and truncation mutants used were previously described30. All plasmid inserts were 
sequenced using GATC.
Dual luciferase assays. Dual luciferase reporter assays were performed as previously described21,24. 
Keratinocytes were seeded at 3 × 105 cells/mL in 24 well dishes the day prior to transfection. Cells were 
transfected with NFκ B-driven firefly luciferase reporter, Renilla luciferase (RLTK) expressing plas-
mid as transfection control, and each of the plasmids encoding HPV proteins using the PEI reagent 
(PolySciences). At 24 hours post transfection cells were stimulated with the appropriate reagents for 
6–24 hours (see figure legends for details – all ligands purchased from Invivogen) prior to lysis in pas-
sive lysis buffer (Promega). Firefly luciferase levels were normalised to Renilla levels and fold induction 
values were calculated relative to the normalised activity of the mock.
CCL20 and IL-6 cytokine assays. Quantities of CCL20 and IL-6 in cell-free supernatants were deter-
mined using the R&D systems DuoSet ELISA kit according to manufacturer’s instructions.
Nuclear fractionation. Control and stimulated cells grown in 10 cm dishes were lysed in cytoplasmic 
lysis buffer (20 mM Tris-HCl pH 7.4, 100 mM NaCl, 5 mM MgCl2, 0.5% NP40 and protease inhibitors) 
by incubation on ice for 30 min with frequent vortexing. The supernatant accounted for the cytoplasmic 
fraction. The nuclear pellet was washed twice in cytoplasmic lysis buffer to reduce cytoplasmic contam-
ination before resuspension in radio-immunoprecipitation (RIPA) buffer. Debris was removed by cen-
trifugation. Samples were then subject to analysis by western blot. Lamin B1 (Calbiochem) and GAPDH 
(Abcam) acted as markers of the nuclear and cytoplasmic fractions.
Western blotting. Primary keratinocytes were stimulated with the appropriate ligand for the time 
indicated in the legend. Media was aspirated and cells washed with ice cold PBS and harvested in Dundee 
lysis buffer38. Lysates were analysed by SDS PAGE and probed with antibodies against p65, acetylated p65 
(Cell Signalling Technology), Lamin B (Calbiochem) and GAPDH (Abcam). Secondary antibodies used 
were HRP-conjugated anti-mouse and anti-rabbit antibodies from Sigma. Blots were developed using 
enhanced chemiluminescence (ECL) reagents (Pierce).
Transcriptome analysis. Total RNA was isolated from cell cultures (approx 3 × 106 cells) using TRIzol 
reagent (Invitrogen, USA) following the manufacturer’s instructions11. Any contaminating genomic DNA 
was removed by incubation with 5U of RNase-free DNase (Promega, UK). Further purification of mRNA 
from total RNA was performed using the Dynabead purification system (Invitrogen, USA) and eluted into 
DEPC-treated H2O. Double-stranded cDNA was synthesised using the SuperScript II double-stranded 
cDNA synthesis kit (Invitrogen, USA). This was purified from the reaction mix using the QIAquick 
DNA extraction system (Qiagen, USA) before quantification by the Quanti-PicoGreen assay (Invitrogen, 
USA) and POLARstar Optima (Optima Scientific, UK). Fractionation of double-stranded cDNA to 200–
300 bp fragments was performed using the Covaris S instrument (Covaris, USA) before end-repair was 
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performed using the Paired-end sequence sample preparation kit (Illumina, USA). Adapter molecules 
were ligated to the cDNA molecules following the protocol of the Paired-End sequence sample prepara-
tion kit (Illumina, USA).
Next-generation sequencing of the ds-cDNA from primary human keratinocytes was performed 
using the Illumina Genome Analyser II (Illumina, USA) following the manufacturer’s recommendations 
in a single-strand manner. Sequencing was performed over 85 cycles with a mean of 43 million reads per 
sample. The .qseq sequence output from the Illumina genome analyser II was converted to the FASTQ 
format before initial screening for the removal of the adapter sequences and PCR artefacts from the reads 
using the FASTX-Toolkit v0.0.13.
FASTQ files generated by next generation sequencing on the Illumina platform were uploaded to 
the Galaxy analysis platform for the alignment to genomes of interest39. Initially FASTQ formatted files 
were converted to FASTQ-Sanger format and analysed for quality across the read length. When tran-
script quality across the read fell below a threshold level the read was trimmed to remove bases of 
poor quality. Read quality varied between samples resulting in different trimming requirements for each 
sample. The trimmed reads were aligned to the human genome using TopHat 1.3.0 program for de novo 
RNA-seq transcript assembly, with a two nucleotide base error incorporation per read (excluding the 
anchor region). This method enabled accurate analysis of gene expression in the analysed samples. The 
.bam files generated by TopHat were indexed before profiling and manual analysis using the Integrated 
Genome Viewer 2.0 (Broad Institute, USA).
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